ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

Advisors Approve NCI Plan To Contract For Early Clinical Trials Of Imaging Agents.

March 31, 2000

In This Issue: Congressional Testimony On NIH, NCI Appropriations, FDA Reform

May 9, 1997

CMS Proposal To Limit ESA Use Is Too Much, Too Fast, Critics Say.

May 18, 2007

“Whatever Happened To…?” ACS Follows Up Five Years Later

August 26, 1977

GAO Report Refutes Charges Against Control Program

May 30, 1980

Newcomers Undercut Price of BRCA Test; Myriad Lawsuits Claim Patent Infringement

July 25, 2013